Detailed Narrative
Q4 FY25 Performance Overview
Illumina exceeded Q4 expectations with $1.16 billion in revenue, driven by strong clinical consumables and NovaSeq X placements. The company achieved 7% ex-China revenue growth in Q4 and expanded non-GAAP operating margins by 400 basis points to 23.7%, reflecting effective cost management and improved operating leverage. For the full year 2025, non-GAAP EPS grew 16% to $4.84, and non-GAAP operating margins expanded by 180 basis points.
Clinical Business Momentum
Clinical consumables revenue grew 20% ex-China in Q4, fueled by increasing adoption of sequencing-based diagnostic tests and a shift towards more data-intensive applications like whole-genome sequencing in oncology and genetic diseases. This trend is driving strong NovaSeq X instrument sales, with over 60% of Q4 placements going to clinical customers. The NovaSeq X conversion for clinical volumes is now more than two-thirds complete, with pricing dynamics increasingly tied to new, higher-volume applications.
Strategic Pillars Execution
Illumina's 2024 strategy focusing on core sequencing, multiomics, and data/software capabilities is yielding results. The NovaSeq X anchors core sequencing, while the SomaLogic acquisition strengthens multiomics offerings, particularly in proteomics. The launch of BioInsight and the Billion Cell Atlas aims to leverage data and AI for drug discovery, attracting collaborations with major biopharma partners like AstraZeneca, Merck, and Eli Lilly. These initiatives are expected to contribute 1-2% growth from 2027 onwards.
Research Market Dynamics
The research market remains cautious due to funding uncertainties, leading to mid-to-high single-digit revenue declines in research and applied consumables. However, signs of stabilization are emerging, including greater clarity on the U.S. NIH funding environment, which could provide future upside. The NovaSeq X transition for research customers is nearing completion, with approximately 90% of high-throughput sequencing volumes converted, expected to dissipate📎 pricing headwinds by H2 2026.
China Market Challenges
Greater China revenue was $55 million in Q4, a $25 million decline YoY, primarily due to export restrictions impacting instrument sales, which were down 55%. The company is working with Chinese regulators to address import challenges, but assumes limited instrument sales in H1 2026. China is expected to be a 1-point headwind to total company revenue growth in FY26, representing less than 5% of the total business.
SomaLogic Integration and Multiomics
The acquisition of SomaLogic, completed on January 30th for an upfront payment of $350 million, significantly enhances Illumina's proteomics capabilities. This integration, along with upcoming spatial transcriptomics and constellation mapped-read technology in H1 2026, aims to deliver integrated, end-to-end workflows for multiomic analysis. SomaLogic is expected to be dilutive to 2026 EPS by $0.18 and impact operating margins by 100 basis points, with management working on synergies.
Long-Term Targets and Capital Allocation
Illumina remains on track for its 2027 targets of high single-digit growth and 26% operating margins, despite the initial dilution from SomaLogic. The company generated $931 million in free cash flow in FY25 and repurchased $740 million in shares. With a clean balance sheet and 1.6x gross leverage, Illumina plans to continue opportunistic share repurchases and evaluate M&A based on specific criteria to drive long-term growth.